Recent News

• 05.07.2026 - Q1 2026 Lantheus Earnings Conference Call
• 05.07.2026 - Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• 04.23.2026 - Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time
• 04.23.2026 - Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time
• 03.25.2026 - FDA Expands Indications for Neuraceq®, an Amyloid PET Imaging Agent, to Enhance Diagnosis and Care of Patients with Alzheimer’s Disease
• 03.17.2026 - Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
• 03.17.2026 - Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
• 03.10.2026 - Leerink Global Healthcare Conference

Recent Filings

• 05.01.2026 - 8-K Current report
• 04.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.20.2026 - ARS Annual Report to Security Holders
• 03.20.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.20.2026 - DEF 14A Other definitive proxy statements
• 03.10.2026 - PRE 14A Other preliminary proxy statements
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities